Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24075353 | 0.83 | RXFP1 (0.42) | POLBRXFP1LMNASMN1; SMN2KMT2A | |
| SCHEMBL5751385 | 0.82 | POLB (0.64) | POLBRXFP1LMNASMN1; SMN2KMT2A | |
| SCHEMBL25834578 | 0.79 | LMNA (0.42) | POLBRXFP1LMNASMN1; SMN2KMT2A | |
| SCHEMBL28821312 | 0.79 | RXFP1 (0.43) | POLBRXFP1LMNASMN1; SMN2KMT2A | |
| SCHEMBL28821310 | 0.79 | RXFP1 (0.43) | POLBRXFP1LMNASMN1; SMN2KMT2A | |
| SCHEMBL24075465 | 0.78 | L3MBTL1 (0.50) | POLBRXFP1LMNASMN1; SMN2KMT2A | |
| SCHEMBL7817956 | 0.77 | POLB (0.59) | POLBRXFP1LMNASMN1; SMN2KMT2A | |
| SCHEMBL24075380 | 0.77 | LMNA (0.48) | POLBRXFP1LMNASMN1; SMN2KDM4E | |
| SCHEMBL31028296 | 0.74 | AAK1 (0.47) | POLBRXFP1LMNASMN1; SMN2KDM4E | |
| SCHEMBL21043305 | 0.73 | KDM4E (0.44) | LMNASMN1; SMN2KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021239077-A1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-12-02 | — | — | WO | disclosed |